Welcome to our dedicated page for Veracyte SEC filings (Ticker: VCYT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Veracyte, Inc. (Nasdaq: VCYT) SEC filings, offering a detailed view into the company’s financial reporting, governance decisions, and key disclosures. Veracyte is a global cancer diagnostics and genomic testing company whose filings reflect its activities in developing and commercializing tests such as Decipher Prostate, Afirma GSC, Prosigna, Decipher Bladder, and the Percepta Nasal Swab test, as well as research platforms like Afirma GRID and Decipher GRID.
Investors can review Veracyte’s periodic reports on Forms 10-K and 10-Q for information about revenue composition, testing volumes, cost structure, and risk factors. Current reports on Form 8-K capture specific events, such as the release of quarterly financial results or shareholder votes. For example, recent 8-K filings describe quarterly earnings press releases and the approval of amendments to the company’s equity incentive plan, along with voting outcomes at the annual meeting of stockholders.
These filings also discuss Veracyte’s use of non-GAAP financial measures, including adjusted EBITDA and adjusted EBITDA margin, and explain which items are excluded from these metrics, such as amortization of acquired intangible assets, acquisition-related expenses, stock-based compensation, and certain restructuring costs. This context helps readers understand how management evaluates the company’s performance relative to GAAP results.
On Stock Titan, Veracyte filings are updated in near real time as they are posted to the SEC’s EDGAR system. AI-powered summaries highlight the main points of lengthy documents, helping users quickly identify key topics such as revenue trends, test portfolio updates, equity plan changes, and shareholder voting results. Users can also monitor forms that may relate to insider activity and executive compensation through the company’s proxy and related disclosures, using the AI tools to navigate complex regulatory language more efficiently.
Robert S. Epstein, a director of Veracyte, Inc. (VCYT), reported transactions on a Form 4 dated 10/01/2025. He exercised 10,000 stock options with an exercise price of $7.94, resulting in 10,000 shares issued, and subsequently sold 21,473 common shares at a weighted average sale price of $35.0768 (individual sales ranged $35.00–$35.30). The Form shows his beneficial ownership changing from 83,919 shares after the option exercise to 62,446 shares following the sale. The transactions were made under a Rule 10b5-1 plan adopted June 5, 2025, and the Form was signed by an attorney-in-fact on 10/03/2025.
An officer of Veracyte, Inc. executed a programmed sale of 2,160 shares of the company's common stock on 10/01/2025 under a Rule 10b5-1 trading plan. The sale's weighted average price was approximately $35.00 per share (individual prices ranged $35.00–$35.05), and the reporting person retained beneficial ownership of 89,439 shares after the transactions. The filer notes the sales were made pursuant to a plan adopted on 9/04/2024, and that detailed per-price share counts are available on request.
Veracyte, Inc. filed a Form 144 reporting a proposed sale of 2,539 shares of common stock through Morgan Stanley Smith Barney LLC on the NASDAQ with an approximate sale date of 10/01/2025. The filing lists an aggregate market value of $87,163.87 based on 78,671,588 shares outstanding. The shares were acquired on 03/02/2024 as restricted stock units issued by the company and were paid on that same date. The filer reports no securities sold in the past three months and certifies they have no undisclosed material adverse information regarding the issuer.
Veracyte (VCYT) reports a proposed sale of 2,160 common shares, representing restricted stock units acquired on 03/02/2025, with an aggregate market value of $74,152.80. The shares are to be sold through Morgan Stanley Smith Barney LLC on or about 10/01/2025 on the NASDAQ. The issuer's outstanding shares are listed as 78,671,588, so the proposed sale equals approximately 0.0027% of outstanding shares. The filing also discloses prior 10b5-1 sales by the same account of 2,283 shares on 09/19/2025 for gross proceeds of $76,919.50. The securities were acquired as Restricted Stock Units from the issuer and no cash payment was required at acquisition.
Annie McGuire, SVP and General Counsel of Veracyte, Inc. (VCYT), reported the sale of 2,283 shares of Veracyte common stock on 09/19/2025 under a pre-established Rule 10b5-1 plan adopted on 09/04/2024. The filing shows a weighted-average sale price of $33.6923 per share, with individual sale prices ranging from $33.50 to $34.00. After the transaction, Ms. McGuire beneficially owned 91,599 shares, reported as direct ownership.
The Form 4 was executed by an attorney-in-fact and explicitly states the sale was made pursuant to the 10b5-1 plan; additional per-price share breakdowns are available on request to the SEC, the issuer, or a shareholder.
Form 144 notice for Veracyte, Inc. (VCYT) reporting a proposed sale of 2,283 common shares, with an aggregate market value of $75,864.09, scheduled approximately for 09/19/2025 on NASDAQ through Morgan Stanley Smith Barney LLC. The shares were acquired as restricted stock units on 06/02/2025 from the issuer and were fully issued on that date. The filer certifies there are no undisclosed material adverse facts and reports no other sales by the same person in the past three months. The filing provides basic transactional details but does not state the seller's identity or motivation for the sale.
Marc Stapley, Chief Executive Officer and Director of Veracyte, Inc. (VCYT), sold 7,667 shares of the company's common stock on 09/04/2025 under a pre-established Rule 10b5-1 trading plan adopted on 09/13/2024. The transaction was reported at a weighted-average sale price of $30.4073, with individual sale prices ranging from $30.22 to $30.66. After the reported sale, the filing shows Mr. Stapley beneficially owns 334,185 shares. The Form 4 was executed by an attorney-in-fact and includes customary disclosure that detailed per-price share breakdowns are available upon request.
Rebecca Chambers, Chief Financial Officer of Veracyte, Inc. (VCYT), reported a Form 4 disclosing that on 09/02/2025 5,371 shares of Common Stock were withheld to satisfy tax withholding obligations related to the vesting of restricted stock units. The filing shows 133,158 shares of Common Stock beneficially owned by the reporting person after the transaction. The transaction code is noted as F and the per-share price listed is $30.11, with the filer confirming the withholding was not a sale but a tax-related retention of shares.
Annie McGuire, SVP and General Counsel of Veracyte, Inc. (VCYT), reported that 3,507 shares of common stock were withheld on 09/02/2025 to satisfy tax withholding tied to the vesting of restricted stock units; this withholding is not a sale and was executed at a per-share price of $30.11. After the withholding, McGuire beneficially owned 93,882 shares, which includes 386 shares purchased on 07/31/2025 under the company’s Employee Stock Purchase Plan. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on 09/04/2025.
Marc Stapley, who is listed as both Chief Executive Officer and a director of Veracyte, Inc. (VCYT), reported a non-sale withholding of 7,914 shares of common stock on 09/02/2025 at an attributable price of $30.11 per share. The withholding satisfied tax obligations arising from the vesting of restricted stock units and therefore was not a market sale. After the transaction Stapley beneficially owned 341,852 shares, which includes 529 shares purchased on 07/31/2025 under the company’s Employee Stock Purchase Plan. The Form 4 was signed by an attorney-in-fact on 09/04/2025.